Showing posts with label plavix. Show all posts
Showing posts with label plavix. Show all posts

Monday, November 8, 2010

The risk of stopping antiplatelet therapy

Antiplatelets , especially Aspirin and Clopidogrel have established their importance in management of coronary artery diseases. But they also pose a bleeding risk. This risk is high if a procedure needing tissue sample is done. We had a 66 yo male ..4 months after a STEMI for which he received a drug eluting stent , and was started on Aspirin and clopidogrel. This clinic visit he is complaining of 6 month h/o early satiety, loss of apetite..and our records show a weight loss of 15lb in last 3 months.He needed a upper GI endoscopy ..with a possible biopsy. What do we do with his antiplatelets? ....Lets look at some facts from AHA
· Cessation of all antiplatelet therapies after PCI, at any time, for any stent, is associated with an increased risk of thrombotic events, including late stent thrombosis. These events are likely to occur within 7 to 30 days of drug discontinuation. 

·Cessation of clopidogrel (alone) during the early period after PCI (within 30 days of either DES or BMS placement) is associated with an increased risk of events. 

·Cessation of clopidogrel (alone) beyond 30 days from the time of BMS placement is common in clinical practice and does not confer increased risk of thrombosis over a brief period of time. 
·Cessation of clopidogrel (alone) upon completion of 6 months of treatment after DES placement is controversial (in terms of long-term risk) but does not seem to confer a significant short-term risk(within the subsequent 30 days) in a majority of patients if aspirin is continued. 

 The importance of continuing aspirin in the above scenarios was shown by a review in JACC 2005, where the median duration of stent thrombosis when both drugs were stopped, was 7 days...compared to 122 days when only clopidogrel was stopped and aspirin was continued.In addition, many retrospective studies have shown safety of continuing aspirin during GI procedures. The GI prcedures have been classified into high & low risk based on the risk of bleeding.
Considering the urgent need for endoscopy, the fact that UGI endoscopy is a low risk for bleeding, and the STEMI 4 months ago....we had our patient continue Aspirin, but stop Clopidogrel 5 days before procedure. He will continue his dual antiplatelet therapy the day after his procedure. As always.....the befits & risks were, and have to be discussed with the patient!

Wednesday, September 29, 2010

combination of Aspirin,Plavix & Warfarin - how bad or how good?

I am sure you had come across those patients who had been on aspirin & warfarin ..or...plavix & warfarin...or rarely all three (either intentionally or by mistake!!). Well...a patient with CAD might benefit more from a antiplatelet...but may need warfarin for A.fib ....will he benefit from both? A recent article from Arch of Int Medicine tried to address these issues by calculating the risk of bleeding associated with each combination.
Lets look at the risk of stoke with A fib at 1 year...so the numbers from the above study would make more sense.

Risk of stroke with A fib - commonly assessed with CHADS2 score
CHADS score of 0,1,2,3,4,5 & 6 carries a 1 year stroke risk of ..roughly 2%,3%, 4%, 6%, 8%, 12% & 18% respectively.So we usually start treatment to prevent this thromboembolic risk by starting them on either antiplatelets or warfarin. This question about warfarin or no warfarin always pops up when we see a patient with A fib.

Now lets see the numbers from the above study where they looked at a cohort of 82,000 patients discharged with a diagnosis of Atrial fibrillation. During a follow up period of 3 years ..11%(13,000 pts) had a fatal or non-fatal bleeding.Having warfarin as the standard ..the hazard ratio for the above end point is as follows
For Aspirin alone - 0.93
for plavix alone - 1.06
for aspirin + plavix - 1.66
for aspirin + warfarin - 1.83
for plavix + warfarin - 3.08
for aspirin +plavix+warfarin - 3.70

Clearly this was something that was expected ..based on previous studies. The crude incidence rate of bleeding was 13% for plavix +warfarin, and 15% for triple therapy. So having these numbers ...gives a better idea for making a risk-benefit decision !! ...So ..whoever your pt is....aspirin+plavix+warfarin seems to be a bad combination!

Monday, August 2, 2010

Stroke and antiplatelets - Aspirin or dipyridamole or plavix?


Todays morning report was about a 63 yo female presenting with slurred speech and some left sided weakness while she was on Aspirin. MRI showed a brainstem infarct. What would be her antiplatelet mnagement?


lets look at some evidence for secondary prevention.There are 2 studies we can quickly look at


1.European Stroke Prevention study (ESPS2) - nearly 7000 patients with TIA/stroke were randomised to ASA or Dipyridamole or both. Primary end point was stroke/death. follw up for 2 years showed a similar risk reduction (13%) in both ASA and dipyridamole groups. The aggrenox group had a 37% risk reduction. Another study ,ESPIRIT in 2006 also showed same benifit.


2. PROFESS trial - this was published in NEJM recently. 20 332 patients from 695 sites in 35 countries. All had had a noncardioembolic ischemic stroke within the previous 120 days.They were randomized to receive Aggrenox bid or clopidogrel (75 mg) once daily.primary outcome was recurrent stroke. There was no difference between the two agents, except for a nonsignificant increase in major hemorrhagic events(4.1% Vs 3.6%). Conclusion- Plavix is not inferior to aggrenox in secondary prevention of stroke.


These two studies (and a few other studies like MATCH which compared ASA with ASA & plavix) made changes to the AHA guidelines for stroke.


The current recommendation is that aggrenox is superior to ASA alone, but all 3 agents(ASA, aggrenox, Plavix) can be used as first line antiplatelets in patients with non carioembolic stroke.